Member Info for crumbs

Great find! :)

Remember... IF!!!! by some blinkin miracle scancell are to be getting a licensing deal for modis off BioNtech... then they will need us to step up and be able to get their TCR's straight into the clinic... and our new recruits sound just the types to be capable of that.

I'm sure it is a vital component as is Scancell having to take on capable staff.. which we have just done...Company X needs to be sure scancell can deliver on all fronts before handing over the cash...

Collaboration over a year old... have those 'candidates' been found ??.... if not what are they still doing if so what is the likely outcome?.... licensing deal or more collaboration ? ...

How the collaboration came about:

'One characteristic of cancer that makes it particularly difficult to treat is its capacity to induce immune suppression, creating a microenvironment within which it can hide. Moditope beats this naturally, without the need for checkpoint inhibitors, which are dogged by concerns over side effects.

By combining this with BioNTech’s T-cell receptor discovery technology, the two companies hope to find candidates that can specifically bind citrullinated epitopes of the cytoskeletal protein, vimentin, and enolase, an enzyme that is essential to glycolysis – an early stage of energy production.'

'This news comes less than a week after BioNTech announced that it had raised a $270M (€225M) Series A to develop personalized cancer immunotherapies using CAR-T, TCR, and mRNA technologies – so it’s no wonder that Scancell is so pleased to be joining forces with them. Lindy Durrant, CSO at Scancell, commented: “We are delighted to be working with BioNTech, one of Europe’s new immuno-oncology power-houses… Pre-clinical data from our Moditope platform has shown unprecedented anti-tumor effects… this, combined with BioNTech’s engineered T cells specific to Moditope epitopes, could have great potential.”

With cancer being such a deadly disease, it makes sense for biotechs to join forces and share their expertise to develop better treatments. British unicorn, Immunocore, has been boosted by support from big pharma partners, including Genentech and GSK, helping it to discover a second lead compound.'

Samantha leaves the unicorn Immunocore to join the Camel

Themselves not any rampers on a BB

Cliff Holloway talking of Sam joining:

'Thats part of a collaboration we have with BioNtech and that project is still ongoing her expertise in T cell cloning will be invaluable as we MOVE that FORWARD'
4:40 https://www.youtube.com/watch?time_continue=3&v=gBTaKD518yY

And Lindy Durrant RNS 21 Jan:
Samantha will report directly to Scancell's founder and Chief Scientific Officer, Professor Lindy Durrant who commented: "Samantha will be invaluable in immunological design of the upcoming trials and SPEARHEADING the NEW TCR THERAPEUTICS and I am very excited to add such an experienced scientist to the team."
http://www.lse.co.uk/share-regulatory-news.asp?shareprice=SCLP&ArticleCode=lqqc85hq&ArticleHeadline=Appoints_Heads_of_Research_and_Manufacturing

So yes no deal announced yet... but no not going to be getting a deal announced either ;)

Certainly no BioNtech deal is done because there is no RNS saying so... however signs are good are they not that that collaboration of over a year old is going well?

Someones got the hump

In an RNS:

"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics and I am very excited to add such an experienced scientist to the team."

scancell have no TCR therapeutics... BioNtect however..... we just need to wait this one out me thinks

I would say if it is not to end commercially and BioNtech are not interested scancell would not have hired Sam and stated 'TCR theraputics' in an RNS...

No guarantee at all however that was the endpoint of the original collaboration... BioNtech get the license .. so you would expect that is how it ends... they are getting ready for trials and stated they will do deals around their TCR platform

Well, it is obvious the BioNtech TCR collaboration is going well and getting to a - next stage.... when we get that RNS I do not know...

Well done Sarah! :)... it is too soon to say if you need psychoanalysis ....one thing we do know this sp can shift upwards very very fast...just need that news

I keep thinking it is overdone on every drop then it goes lower and lower... been nibbling away all the way down.. next for me will be next week.. unless some amazing event arrives to turn the tide... we are surely due half yearly?... all seems very quiet as this BioNtech collab plays out... and we await on FDA to reply

My fantasy about her is she will buy a million shares at 8 lol

I bet Sarah is lovely though :)...

Samantha you mean:) ... no half-year RNS appeared

Be a BioNtech TCR trial this year... will it involve scancell... well this is what BioNtech said after they recently did their MABs deal...and from the recruitment drive you can see on their website it looks likely they will have some form of CAR T/TCR clinical program in place this year.

“If you look at our approach, we do have vaccines. We do have other mRNA programs. We have non-mRNA platforms—for example, we have an antigen-specific T cell receptors (TCRs) platform, a chimeric antigen receptors (CARs) platform, we have a bispecific antibody platform, we have a small molecule platform. And in fact, some of those other platforms will be bringing candidates into the clinic this year,” Marett said, without disclosing which platforms or which candidates will advance to clinical phases.'

All Merck KGaA needed to do was call Lindy... why they don't is the biggest of mysteries...

Cancer vaccine fails... yet we know one that did not but seemingly no one wants commercially in on it... though the top clinicians see its potential...

'“There’s many unanswered questions in regards to the LICC study and in regards to cancer vaccines in general,” Dr. Overman noted. Among them, what are the optimal antigens to target, what are the optimal vaccine formulations and adjuvant agents, what is the best way to address the immunosuppressive tumor microenvironment, and what is the correct disease setting for vaccine testing?'
https://www.mdedge.com/hematology-oncology/article/193444/gastroenterology/cancer-vaccine-fails-crc-trial-yields-lessons